Gras Julien, De Castro Nathalie, Montlahuc Claire, Champion Laure, Scemla Anne, Matignon Marie, Lachâtre Marie, Raskine Laurent, Grall Nathalie, Peraldi Marie Noëlle, Molina Jean Michel
Service de Maladies infectieuses et tropicales, APHP-Hôpital Saint Louis, Paris, France.
Service de Biostatistiques et Information médicale, Hôpital Saint Louis APHP, Paris ECSTRA Team, UMR 1153 INSERM, Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
Transpl Infect Dis. 2018 Oct;20(5):e12943. doi: 10.1111/tid.12943. Epub 2018 Jun 28.
Tuberculosis (TB) is a rare but life-threatening infection after solid organ transplant. The present study was undertaken to assess the clinical features, risk factors, and outcome of TB after kidney transplantation in a low-prevalence area.
We conducted a retrospective study, describing all kidney transplant recipients diagnosed with TB between 2005 and 2015 in 3 French centers. For each TB case, 2 controls without TB were identified and matched by center, age, transplant date, and birth country. Risk factors associated with TB were identified and survival estimated.
Thirty-two cases and 64 control patients were included among 3974 transplantations. The prevalence of TB was 0.83%. Median age at the time of diagnosis was 64 years; 75% were born in a high TB prevalence country, but only 3 had received isoniazid prophylaxis for latent TB infection. TB occurred at a median of 22 months after transplantation. On diagnosis, 66% had disseminated infection. Median duration of treatment was 9 months. Immunosuppressive therapy changes were necessary in all patients because of drug-drug interactions. Among cases, 5 deaths occurred during follow-up (median duration: 41 months), one directly related with TB. Survival was significantly lower in transplant recipients with TB, as compared to controls (P = .001). No predictive factors of tuberculosis after transplantation were statistically significant in univariate analysis.
TB in kidney transplant recipients is a rare and late event, but is associated with significantly reduced survival. Our results emphasize the need for systematic screening for LTBI, followed by IPT in high-risk patients.
结核病(TB)是实体器官移植后一种罕见但危及生命的感染。本研究旨在评估低流行地区肾移植后结核病的临床特征、危险因素及预后。
我们进行了一项回顾性研究,描述了2005年至2015年间在法国3个中心被诊断为结核病的所有肾移植受者。对于每例结核病病例,确定2名无结核病的对照者,并按中心、年龄、移植日期和出生国家进行匹配。确定与结核病相关的危险因素并估计生存率。
3974例移植中有32例病例和64例对照患者被纳入研究。结核病的患病率为0.83%。诊断时的中位年龄为64岁;75%出生在结核病高流行国家,但只有3人接受过潜伏性结核感染的异烟肼预防性治疗。结核病发生在移植后的中位时间为22个月。诊断时,66%有播散性感染。中位治疗持续时间为9个月。由于药物相互作用,所有患者都需要改变免疫抑制治疗方案。在病例组中,随访期间有5例死亡(中位持续时间:41个月),1例与结核病直接相关。与对照组相比,结核病肾移植受者的生存率显著降低(P = 0.001)。在单因素分析中,移植后结核病的预测因素均无统计学意义。
肾移植受者中的结核病是一种罕见且发生较晚的事件,但与生存率显著降低相关。我们的结果强调了对潜伏性结核感染进行系统筛查的必要性,随后对高危患者进行预防性治疗。